COVID-19 knowledge prevents biologics discontinuation: Data from an Italian multicenter survey during RED-ZONE declaration.
Adult
Betacoronavirus
Biological Products
/ therapeutic use
COVID-19
Comorbidity
Coronavirus Infections
/ epidemiology
Cross-Sectional Studies
Female
Follow-Up Studies
Health Knowledge, Attitudes, Practice
Humans
Italy
/ epidemiology
Male
Pandemics
Pneumonia, Viral
/ epidemiology
Prognosis
Retrospective Studies
SARS-CoV-2
Skin Diseases
/ drug therapy
Surveys and Questionnaires
COVID-19
COVID-19 questionnaire
SARS-CoV-2
atopic dermatitis
biologics
hidradenitis suppurativa
psoriasis
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
15
04
2020
revised:
23
04
2020
accepted:
28
04
2020
pubmed:
18
5
2020
medline:
26
11
2020
entrez:
17
5
2020
Statut:
ppublish
Résumé
SARS-CoV-2 become pandemics and there is still a dearth of data about its the potentially among dermatological patients under biologics. We aimed to assess health literacy, disease knowledge, treatment dissatisfaction and biologics attitudes toward COVID-19. We performed a cross-sectional, questionnaire-based survey on 98/105 consecutive dermatological patients treated with biologics-51 suffering from plaque psoriasis, 22 from atopic dermatitis, and 25 from hidradenitis suppurativa. An ad hoc, validated questionnaire has 44 items investigating the following domains: knowledge of COVID-19 related to (a) epidemiology, (b) pathogenesis, (c) clinical symptoms, (d) preventive measures, and (e) attitudes. Patients data and questionnaires were collected. Despite only 8.1% thought that biologics may increase the risk of COVID-19, 18.4% and 21.4% of the patients were evaluating the possibility to discontinue or modify the dosage of the current biologic therapy, respectively. Globally, male patients (P = .001) with higher scholarity level (P = .005) displayed higher knowledge of COVID-19. Patients with lower DLQI (P = .006), longer disease duration (P = .051) and lower scholarity (P = .007) have thought to discontinue/modify autonomously their biologic therapy. At the multivariate logistic regression, only the knowledge of epidemiology and preventive measures resulted independent predictors of continuation vs discontinuation and modification vs no modification, respectively. Dermatologists should promote COVID-19 knowledge to prevent biologics disruption.
Identifiants
pubmed: 32415727
doi: 10.1111/dth.13508
pmc: PMC7267153
doi:
Substances chimiques
Biological Products
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13508Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Br J Dermatol. 2015 Dec;173(6):1544-5
pubmed: 26130316
Liver Transpl. 2020 Jun;26(6):832-834
pubmed: 32196933
G Ital Dermatol Venereol. 2019 Jun;154(3):227-253
pubmed: 30717577
Dermatol Ther. 2020 Jul;33(4):e13298
pubmed: 32157783
Dermatol Ther. 2020 Sep;33(5):e13475
pubmed: 32356577
J Autoimmun. 2020 May;109:102433
pubmed: 32113704
J Dermatol Sci. 2019 May;94(2):266-275
pubmed: 31109652
Am J Transplant. 2020 Jul;20(7):1939-1940
pubmed: 32181969
Biomed Res Int. 2018 Sep 23;2018:3140682
pubmed: 30345297
Ann Rheum Dis. 2020 Feb;79(2):285-291
pubmed: 31672774
Acta Biomed. 2020 May 11;91(2):57-67
pubmed: 32420926
N Engl J Med. 2020 May 14;382(20):1873-1875
pubmed: 32187459
J Am Acad Dermatol. 2020 Apr;82(4):1006-1011
pubmed: 31678467
N Engl J Med. 2016 Aug 4;375(5):422-34
pubmed: 27518661
J Am Acad Dermatol. 2020 May;82(5):1215-1216
pubmed: 32171808
Clin Infect Dis. 2020 Jul 28;71(15):769-777
pubmed: 32176772
Br J Dermatol. 2017 Nov;177(5):1401-1409
pubmed: 28636793
Br J Dermatol. 2016 Oct;175(4):797-9
pubmed: 26991762
Dermatologica. 1978;157(4):238-44
pubmed: 357213
J Eur Acad Dermatol Venereol. 2019 Oct;33(10):1913-1920
pubmed: 31177583
Br J Dermatol. 2020 Aug;183(2):375-376
pubmed: 32302419
J Am Acad Dermatol. 2020 May;82(5):1085-1086
pubmed: 32171807
Dermatol Online J. 2017 Apr 15;23(4):
pubmed: 28541882
Clin Exp Dermatol. 1994 May;19(3):210-6
pubmed: 8033378
J Eur Acad Dermatol Venereol. 2017 May;31(5):774-790
pubmed: 28244153
J Asthma. 2019 Oct;56(10):1110-1119
pubmed: 30273510
Dermatol Ther. 2019 Nov;32(6):e13121
pubmed: 31625221
Exp Dermatol. 2001 Feb;10(1):11-8
pubmed: 11168575
J Am Acad Dermatol. 2016 Jun;74(6):1057-1065.e4
pubmed: 26946986
J Am Acad Dermatol. 2020 Jul;83(1):246-248
pubmed: 31940465
G Ital Dermatol Venereol. 2015 Dec;150(6):731-9
pubmed: 26513043
Int J Infect Dis. 2020 May;94:44-48
pubmed: 32171952
J Eur Acad Dermatol Venereol. 2018 Nov;32(11):1993-1998
pubmed: 29729101
Int Arch Allergy Immunol. 2020;181(1):1-10
pubmed: 31593946
Ann Rheum Dis. 2010 Mar;69(3):546-9
pubmed: 19762363
JAMA. 2020 May 12;323(18):1775-1776
pubmed: 32203977
J Eur Acad Dermatol Venereol. 2020 May;34(5):e213-e214
pubmed: 32201972
Lancet Glob Health. 2020 May;8(5):e641-e642
pubmed: 32199072
J Dermatolog Treat. 2019 Sep;30(6):525-528
pubmed: 29790405
Ann Rheum Dis. 2017 Aug;76(8):e25
pubmed: 28011453
Dermatol Ther. 2020 Jul;33(4):e13508
pubmed: 32415727
J Am Acad Dermatol. 2020 May;82(5):1217-1218
pubmed: 32199889
Eur J Intern Med. 2020 May;75:107-108
pubmed: 32192856
Mayo Clin Proc. 2011 Apr;86(4):304-14
pubmed: 21389250
Clin Exp Rheumatol. 2020 Mar-Apr;38(2):337-342
pubmed: 32202240
Psoriasis (Auckl). 2016 May 27;6:65-71
pubmed: 29387595